

## PRESS RELEASE

### LIFE SCIENCES COMPANY M2i RECEIVES €12 MILLION IN FUNDING FROM IDINVEST PARTNERS

Paris, June 26th, 2017

Idinvest Partners today announced €12 million in funding for life sciences company M2i as part of the firm's continued support of high-growth European SMEs. The funds raised will enable biocontrol producer M2i to finance the approval process of its Biocontrol products, pursue its R&D investment strategy and accelerate its international development.

M2i Life Sciences is a world leader in the field of pheromones for crop protection, animal health and human health, producing agricultural chemical products in the Biocontrol sector. Addressing the issue of tackling increasing resistance and toxicity of insecticides and GMOs, the company provides innovative alternative solutions for all methods of biological protection.

Matthieu Baret, Partner at Idinvest, commented: "This investment comes from the Idinvest Growth Fund II which targets small-mid cap companies that have the potential to expand globally and become industry leaders within the Digital, Health and Smart Cities sectors." Following a first close of 250 million euros at the end of 2016, Idinvest is targeting between 350 and 400 million euros for a final close in 2017. Since its launch 6 months ago, the fund has invested in three European SMEs, Vestiaire Collective, an online marketplace for luxury goods and IoT business Actility.

Emmanelle Pierret, Investment Director at Idinvest Partners, commented "M2i provides an unprecedented response to the challenges of respecting the environment and protecting biodiversity. The effectiveness of their products has already been demonstrated, in particular on field crops that have not yet been equipped with Biocontrol solutions, and we are very happy to be supporting them in their next stage of growth."

Philippe Guerret, President of M2i group, added: "Over 4 years, M2i has built a vast range of solutions for a profitable, sustainable and environmentally friendly agriculture. This partnership with Idinvest will allow us to continue to commercially deploy these solutions at an even faster pace, and also continue to expand our portfolio."

## ABOUT IDINVEST PARTNERS

With almost €8 billion under management, Idinvest Partners is a leading pan-European private equity firm focused on the mid-market segment. Idinvest Partners has developed several complementary areas of expertise including: investments in innovative European start-ups; mid-market direct lending (unitranche, senior loans and junior financing); primary and secondary investments in unlisted European companies, and private equity consulting. Founded under the name AGF Private Equity in 1997, Idinvest Partners was formerly part of Allianz until 2010 when it became an independent firm.

### About M2i Life Sciences:

Founded in 2013, M2i is a French industrial group, expert in the design, formulation and production of complex molecules. With its research laboratory in Lacq (Aquitaine), combined with its production plant in Salin de Giraud (Provence-Alpes-Côte d'Azur) and its manufacturing center in Parnac (Midi-Pyrenees), M2i caters for the needs of its customers in three sectors: human health, animal biocontrol and plant biocontrol.

M2i has developed its own expertise in pheromones for biological protection of crops and animal welfare. It designs, manufactures and markets a new generation of natural products that can replace traditional pesticides efficiently and cost-effectively. For this reason the group received in 2015 the Enterprise & Environment Award from the French Ministry of Ecology and Sustainable Development, in the Innovation category, as well as the RMC SME 2016 Trophy.

M2i employs 110 people, more than a quarter in R & D, and holds 12 patent families protecting its technology and its innovative product ranges.

**M2i Life Sciences, an industrial ambition serving excellence and innovation.**

For more information [www.m2i-lifesciences.com](http://www.m2i-lifesciences.com)

[www.idinvest.com](http://www.idinvest.com)

**CONTACTS PRESSE**

**IDINVEST PARTNERS**

**Marie-Claire Martin**

[mcm@idinvest.com](mailto:mcm@idinvest.com)

+33 1 58 18 56 69

**PROSEK PARTNERS**

**Henrietta Dehn**

[hdehn@prosek.com](mailto:hdehn@prosek.com)

+44 (0)20 3878 8560

**M2i LIFE SCIENCES**

**Johann Fournil**

[contact.presse@m2i-lifesciences.com](mailto:contact.presse@m2i-lifesciences.com)

+33 1 84 76 00 64